体外肺モデルの市場規模、シェア、動向分析レポート:タイプ別(2Dモデル、3Dモデル)、用途別(生理学研究、3Dモデル開発)、最終用途別、地域別、セグメント別予測、2024年~2030年In Vitro Lung Model Market Size, Share & Trends Analysis Report By Type (2D Model, 3D Model), By Application (Physiological Research, 3D Model Development), By End-use, By Region, And Segment Forecasts, 2024 - 2030 体外肺モデル市場の成長と動向 Grand View Research社の最新レポートによると、世界の体外肺モデル市場規模は2030年までに9億4810万米ドルに達し、2024年から2030年までのCAGRは17.4%で成長すると予測されて... もっと見る
1~3営業日
サマリー体外肺モデル市場の成長と動向Grand View Research社の最新レポートによると、世界の体外肺モデル市場規模は2030年までに9億4810万米ドルに達し、2024年から2030年までのCAGRは17.4%で成長すると予測されている。市場成長を促進する要因としては、動物実験モデルの代替品作りに重点が置かれるようになっていること、ここ数年の呼吸器関連疾患の世界的な増加などが挙げられる。試験管内肺モデルは、研究者が特定の呼吸器疾患を再現し、潜在的な治療オプションを開発するためにこれらの疾患の細胞および分子特性を密接に模倣するのに役立ちます。このように、疾患のモデル化は試験管内肺モデルの全体的な成長に寄与している。さらに、米国動物愛護協会(HSUS)の報告によれば、米国では毎年約5000万匹の動物が実験に使用されている。動物に対する残酷な行為を軽減するために、動物福祉法(AWA)は動物に対する有害な実験を減らすことを目的とした規制を設けている。 このように、ここ数年、研究分野における動物の倫理的扱いに関する世界的な認識と関心が顕著になってきている。この強調は、試験管内肺モデルに対する世界的な需要の増加に寄与している。さらに、動物を用いた維持や試験には費用がかかるが、in vitroモデルを用いれば、特に化合物や化学物質のハイスループットスクリーニングにおいて、費用対効果が高くなる。この費用対効果の高さは、予算が限られている研究者や組織にとって魅力的であり、試験管内モデルを動物実験に代わる信頼性の高いものにしている。主要参入企業は、世界的な足跡と製品ポートフォリオを拡大するため、パートナーシップ、M&A、契約、製品発表など、さまざまな戦略を採用している。例えば、2023年6月、AlveoliX社は、革新的な3D構造機能を含む新しい臓器オンチップシステムを発表し、あらゆる臓器の模倣をより便利にした。 体外肺モデル市場レポートハイライト - 利便性、効率性、包括的な性質により、2Dモデルタイプが2023年の市場を独占 - 創薬・毒性試験用途が2023年に市場を席巻、製薬研究開発の初期段階で重要な役割を果たすため - 最終用途別では、医薬品開発・研究における重要な役割から、製薬・バイオテクノロジー企業が2023年の市場を支配した。 - 北米は、同地域に主要企業や学術研究機関が存在することから、2023年に同産業を支配した。 - 同市場で事業を展開する主要企業は、市場ポジションを維持するため、製品の上市、提携、地理的拡大に絶えず注力している。 目次Table of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation & Scope 1.2. Market Definitions 1.2.1. Information Analysis 1.2.2. Market Application & Data Visualization 1.2.3. Data Validation & Publishing 1.3. Research Assumptions 1.4. Information Procurement 1.4.1. Primary Research 1.5. Information or Data Analysis 1.6. Market Application & Validation 1.7. Market Model 1.8. Global Market: CAGR Calculation 1.9. Objectives 1.9.1. Objective 1: 1.9.2. Objective 2: Chapter 2. Executive Summary 2.1. Market Snapshot 2.2. Segment Snapshot 2.3. Competitive Landscape Snapshot Chapter 3. Market Variables, Trends, & Scope 3.1. Market Lineage Outlook 3.1.1. Parent Market Outlook 3.1.2. Related/Ancillary Market Outlook 3.2. Market Dynamics 3.2.1. Market Driver Analysis 3.2.1.1. Rising prevalence of respiratory diseases 3.2.1.2. Advancement in cell culture technology 3.2.1.3. Increasing number of research activities being done towards pulmonary drug development 3.2.2. Market Restraint Analysis 3.2.2.1. Lack of skilled professional 3.3. Industry Analysis Tools 3.3.1. Porter’s Five Forces Analysis 3.3.2. PESTEL Analysis 3.3.3. COVID-19 Impact Analysis Chapter 4. Type Business Analysis 4.1. In Vitro Lung Model Market: Product Movement Analysis 4.2. 2D Model 4.2.1. 2D Model Market, 2018 - 2030 (USD Million) 4.3. 3D Model 4.3.1. 3D Model Market, 2018 - 2030 (USD Million) Chapter 5. Application Business Analysis 5.1. In Vitro Lung Model Market: Application Movement Analysis 5.2. Drug discovery and Toxicology Studies 5.2.1. Drug discovery and toxicology studies Market, 2018 - 2030 (USD Million) 5.3. Physiological Research 5.3.1. Physiological Research Market, 2018 - 2030 (USD Million) 5.4. 3D Model Development 5.4.1. 3D Model Development Market, 2018 - 2030 (USD Million) 5.5. Others 5.5.1. Others Market, 2018 - 2030 (USD Million) Chapter 6. End-use Business Analysis 6.1. In Vitro Lung Model Market: End-use Movement Analysis 6.2. Academic Research Institutes 6.2.1. Academic Research Institutes Market, 2018 - 2030 (USD Million) 6.3. Pharmaceutical and Biotechnology Companies 6.3.1. Pharmaceutical and Biotechnology Companies Market, 2018 - 2030 (USD Million) 6.4. Others 6.4.1. Others Market, 2018 - 2030 (USD Million) Chapter 7. Regional Business Analysis 7.1. In Vitro Lung Model Market Share By Region, 2023 & 2030 7.2. North America 7.2.1. North America In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.2.2. U.S. 7.2.2.1. Key Country Dynamics 7.2.2.2. Competitive Scenario 7.2.2.3. Regulatory Framework 7.2.2.4. U.S. In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.2.3. Canada 7.2.3.1. Key Country Dynamics 7.2.3.2. Competitive Scenario 7.2.3.3. Regulatory Framework 7.2.3.4. Canada In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.3. Europe 7.3.1. Europe In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.3.2. UK 7.3.2.1. Key Country Dynamics 7.3.2.2. Competitive Scenario 7.3.2.3. Regulatory Framework 7.3.2.4. UK In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.3.3. Germany 7.3.3.1. Key Country Dynamics 7.3.3.2. Competitive Scenario 7.3.3.3. Regulatory Framework 7.3.3.4. Germany In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.3.4. France 7.3.4.1. Key Country Dynamics 7.3.4.2. Competitive Scenario 7.3.4.3. Regulatory Framework 7.3.4.4. France In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.3.5. Italy 7.3.5.1. Key Country Dynamics 7.3.5.2. Competitive Scenario 7.3.5.3. Regulatory Framework 7.3.5.4. Italy In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.3.6. Spain 7.3.6.1. Key Country Dynamics 7.3.6.2. Competitive Scenario 7.3.6.3. Regulatory Framework 7.3.6.4. Spain In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.3.7. Denmark 7.3.7.1. Key Country Dynamics 7.3.7.2. Competitive Scenario 7.3.7.3. Regulatory Framework 7.3.7.4. Denmark In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.3.8. Sweden 7.3.8.1. Key Country Dynamics 7.3.8.2. Competitive Scenario 7.3.8.3. Regulatory Framework 7.3.8.4. Sweden In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.3.9. Norway 7.3.9.1. Key Country Dynamics 7.3.9.2. Competitive Scenario 7.3.9.3. Regulatory Framework 7.3.9.4. Norway In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.4. Asia Pacific 7.4.1. Asia Pacific In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.4.2. Japan 7.4.2.1. Key Country Dynamics 7.4.2.2. Competitive Scenario 7.4.2.3. Regulatory Framework 7.4.2.4. Japan In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.4.3. China 7.4.3.1. Key Country Dynamics 7.4.3.2. Competitive Scenario 7.4.3.3. Regulatory Framework 7.4.3.4. China In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.4.4. India 7.4.4.1. Key Country Dynamics 7.4.4.2. Competitive Scenario 7.4.4.3. Regulatory Framework 7.4.4.4. India In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.4.5. Australia 7.4.5.1. Key Country Dynamics 7.4.5.2. Competitive Scenario 7.4.5.3. Regulatory Framework 7.4.5.4. Australia In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.4.6. Thailand 7.4.6.1. Key Country Dynamics 7.4.6.2. Competitive Scenario 7.4.6.3. Regulatory Framework 7.4.6.4. Thailand In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.4.7. South Korea 7.4.7.1. Key Country Dynamics 7.4.7.2. Competitive Scenario 7.4.7.3. Regulatory Framework 7.4.7.4. South Korea In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.5. Latin America 7.5.1. Latin America In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.5.2. Brazil 7.5.2.1. Key Country Dynamics 7.5.2.2. Competitive Scenario 7.5.2.3. Regulatory Framework 7.5.2.4. Brazil In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.5.3. Mexico 7.5.3.1. Key Country Dynamics 7.5.3.2. Competitive Scenario 7.5.3.3. Regulatory Framework 7.5.3.4. Mexico In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.5.4. Argentina 7.5.4.1. Key Country Dynamics 7.5.4.2. Competitive Scenario 7.5.4.3. Regulatory Framework 7.5.4.4. Argentina In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.6. MEA 7.6.1. MEA In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.6.2. South Africa 7.6.2.1. Key Country Dynamics 7.6.2.2. Competitive Scenario 7.6.2.3. Regulatory Framework 7.6.2.4. South Africa In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.6.3. Saudi Arabia 7.6.3.1. Key Country Dynamics 7.6.3.2. Competitive Scenario 7.6.3.3. Regulatory Framework 7.6.3.4. Saudi Arabia In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.6.4. UAE 7.6.4.1. Key Country Dynamics 7.6.4.2. Competitive Scenario 7.6.4.3. Regulatory Framework 7.6.4.4. UAE In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.6.5. Kuwait 7.6.5.1. Key Country Dynamics 7.6.5.2. Competitive Scenario 7.6.5.3. Regulatory Framework 7.6.5.4. Kuwait In Vitro Lung Model Market, 2018 - 2030 (USD Million) Chapter 8. Competitive Landscape 8.1. Company Categorization 8.2. Strategy Mapping 8.3. Company Market Position Analysis, 2023 8.4. Company Profiles 8.4.1. Epithelix 8.4.1.1. Overview 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.1.3. Product Benchmarking 8.4.1.4. Strategic Initiatives 8.4.2. MATTEK 8.4.2.1. Overview 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.2.3. Product Benchmarking 8.4.2.4. Strategic Initiatives 8.4.3. MIMETAS 8.4.3.1. Overview 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.3.3. Product Benchmarking 8.4.3.4. Strategic Initiatives 8.4.4. Lonza 8.4.4.1. Overview 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.4.3. Product Benchmarking 8.4.4.4. Strategic Initiatives 8.4.5. Emulate 8.4.5.1. Overview 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.5.3. Product Benchmarking 8.4.5.4. Strategic Initiatives 8.4.6. AlveoliX AG 8.4.6.1. Overview 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.6.3. Product Benchmarking 8.4.6.4. Strategic Initiatives 8.4.7. InSphero 8.4.7.1. Overview 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.7.3. Product Benchmarking 8.4.7.4. Strategic Initiatives 8.4.8. CN Bio Innovations Ltd 8.4.8.1. Overview 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.8.3. Product Benchmarking 8.4.8.4. Strategic Initiatives 8.4.9. ATTC Global 8.4.9.1. Overview 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.9.3. Product Benchmarking 8.4.9.4. Strategic Initiatives 8.4.10. TissUse GmbH 8.4.10.1. Overview 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.10.3. Product Benchmarking 8.4.10.4. Strategic Initiatives
SummaryIn Vitro Lung Model Market Growth & Trends Table of ContentsTable of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation & Scope 1.2. Market Definitions 1.2.1. Information Analysis 1.2.2. Market Application & Data Visualization 1.2.3. Data Validation & Publishing 1.3. Research Assumptions 1.4. Information Procurement 1.4.1. Primary Research 1.5. Information or Data Analysis 1.6. Market Application & Validation 1.7. Market Model 1.8. Global Market: CAGR Calculation 1.9. Objectives 1.9.1. Objective 1: 1.9.2. Objective 2: Chapter 2. Executive Summary 2.1. Market Snapshot 2.2. Segment Snapshot 2.3. Competitive Landscape Snapshot Chapter 3. Market Variables, Trends, & Scope 3.1. Market Lineage Outlook 3.1.1. Parent Market Outlook 3.1.2. Related/Ancillary Market Outlook 3.2. Market Dynamics 3.2.1. Market Driver Analysis 3.2.1.1. Rising prevalence of respiratory diseases 3.2.1.2. Advancement in cell culture technology 3.2.1.3. Increasing number of research activities being done towards pulmonary drug development 3.2.2. Market Restraint Analysis 3.2.2.1. Lack of skilled professional 3.3. Industry Analysis Tools 3.3.1. Porter’s Five Forces Analysis 3.3.2. PESTEL Analysis 3.3.3. COVID-19 Impact Analysis Chapter 4. Type Business Analysis 4.1. In Vitro Lung Model Market: Product Movement Analysis 4.2. 2D Model 4.2.1. 2D Model Market, 2018 - 2030 (USD Million) 4.3. 3D Model 4.3.1. 3D Model Market, 2018 - 2030 (USD Million) Chapter 5. Application Business Analysis 5.1. In Vitro Lung Model Market: Application Movement Analysis 5.2. Drug discovery and Toxicology Studies 5.2.1. Drug discovery and toxicology studies Market, 2018 - 2030 (USD Million) 5.3. Physiological Research 5.3.1. Physiological Research Market, 2018 - 2030 (USD Million) 5.4. 3D Model Development 5.4.1. 3D Model Development Market, 2018 - 2030 (USD Million) 5.5. Others 5.5.1. Others Market, 2018 - 2030 (USD Million) Chapter 6. End-use Business Analysis 6.1. In Vitro Lung Model Market: End-use Movement Analysis 6.2. Academic Research Institutes 6.2.1. Academic Research Institutes Market, 2018 - 2030 (USD Million) 6.3. Pharmaceutical and Biotechnology Companies 6.3.1. Pharmaceutical and Biotechnology Companies Market, 2018 - 2030 (USD Million) 6.4. Others 6.4.1. Others Market, 2018 - 2030 (USD Million) Chapter 7. Regional Business Analysis 7.1. In Vitro Lung Model Market Share By Region, 2023 & 2030 7.2. North America 7.2.1. North America In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.2.2. U.S. 7.2.2.1. Key Country Dynamics 7.2.2.2. Competitive Scenario 7.2.2.3. Regulatory Framework 7.2.2.4. U.S. In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.2.3. Canada 7.2.3.1. Key Country Dynamics 7.2.3.2. Competitive Scenario 7.2.3.3. Regulatory Framework 7.2.3.4. Canada In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.3. Europe 7.3.1. Europe In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.3.2. UK 7.3.2.1. Key Country Dynamics 7.3.2.2. Competitive Scenario 7.3.2.3. Regulatory Framework 7.3.2.4. UK In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.3.3. Germany 7.3.3.1. Key Country Dynamics 7.3.3.2. Competitive Scenario 7.3.3.3. Regulatory Framework 7.3.3.4. Germany In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.3.4. France 7.3.4.1. Key Country Dynamics 7.3.4.2. Competitive Scenario 7.3.4.3. Regulatory Framework 7.3.4.4. France In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.3.5. Italy 7.3.5.1. Key Country Dynamics 7.3.5.2. Competitive Scenario 7.3.5.3. Regulatory Framework 7.3.5.4. Italy In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.3.6. Spain 7.3.6.1. Key Country Dynamics 7.3.6.2. Competitive Scenario 7.3.6.3. Regulatory Framework 7.3.6.4. Spain In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.3.7. Denmark 7.3.7.1. Key Country Dynamics 7.3.7.2. Competitive Scenario 7.3.7.3. Regulatory Framework 7.3.7.4. Denmark In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.3.8. Sweden 7.3.8.1. Key Country Dynamics 7.3.8.2. Competitive Scenario 7.3.8.3. Regulatory Framework 7.3.8.4. Sweden In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.3.9. Norway 7.3.9.1. Key Country Dynamics 7.3.9.2. Competitive Scenario 7.3.9.3. Regulatory Framework 7.3.9.4. Norway In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.4. Asia Pacific 7.4.1. Asia Pacific In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.4.2. Japan 7.4.2.1. Key Country Dynamics 7.4.2.2. Competitive Scenario 7.4.2.3. Regulatory Framework 7.4.2.4. Japan In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.4.3. China 7.4.3.1. Key Country Dynamics 7.4.3.2. Competitive Scenario 7.4.3.3. Regulatory Framework 7.4.3.4. China In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.4.4. India 7.4.4.1. Key Country Dynamics 7.4.4.2. Competitive Scenario 7.4.4.3. Regulatory Framework 7.4.4.4. India In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.4.5. Australia 7.4.5.1. Key Country Dynamics 7.4.5.2. Competitive Scenario 7.4.5.3. Regulatory Framework 7.4.5.4. Australia In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.4.6. Thailand 7.4.6.1. Key Country Dynamics 7.4.6.2. Competitive Scenario 7.4.6.3. Regulatory Framework 7.4.6.4. Thailand In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.4.7. South Korea 7.4.7.1. Key Country Dynamics 7.4.7.2. Competitive Scenario 7.4.7.3. Regulatory Framework 7.4.7.4. South Korea In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.5. Latin America 7.5.1. Latin America In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.5.2. Brazil 7.5.2.1. Key Country Dynamics 7.5.2.2. Competitive Scenario 7.5.2.3. Regulatory Framework 7.5.2.4. Brazil In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.5.3. Mexico 7.5.3.1. Key Country Dynamics 7.5.3.2. Competitive Scenario 7.5.3.3. Regulatory Framework 7.5.3.4. Mexico In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.5.4. Argentina 7.5.4.1. Key Country Dynamics 7.5.4.2. Competitive Scenario 7.5.4.3. Regulatory Framework 7.5.4.4. Argentina In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.6. MEA 7.6.1. MEA In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.6.2. South Africa 7.6.2.1. Key Country Dynamics 7.6.2.2. Competitive Scenario 7.6.2.3. Regulatory Framework 7.6.2.4. South Africa In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.6.3. Saudi Arabia 7.6.3.1. Key Country Dynamics 7.6.3.2. Competitive Scenario 7.6.3.3. Regulatory Framework 7.6.3.4. Saudi Arabia In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.6.4. UAE 7.6.4.1. Key Country Dynamics 7.6.4.2. Competitive Scenario 7.6.4.3. Regulatory Framework 7.6.4.4. UAE In Vitro Lung Model Market, 2018 - 2030 (USD Million) 7.6.5. Kuwait 7.6.5.1. Key Country Dynamics 7.6.5.2. Competitive Scenario 7.6.5.3. Regulatory Framework 7.6.5.4. Kuwait In Vitro Lung Model Market, 2018 - 2030 (USD Million) Chapter 8. Competitive Landscape 8.1. Company Categorization 8.2. Strategy Mapping 8.3. Company Market Position Analysis, 2023 8.4. Company Profiles 8.4.1. Epithelix 8.4.1.1. Overview 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.1.3. Product Benchmarking 8.4.1.4. Strategic Initiatives 8.4.2. MATTEK 8.4.2.1. Overview 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.2.3. Product Benchmarking 8.4.2.4. Strategic Initiatives 8.4.3. MIMETAS 8.4.3.1. Overview 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.3.3. Product Benchmarking 8.4.3.4. Strategic Initiatives 8.4.4. Lonza 8.4.4.1. Overview 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.4.3. Product Benchmarking 8.4.4.4. Strategic Initiatives 8.4.5. Emulate 8.4.5.1. Overview 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.5.3. Product Benchmarking 8.4.5.4. Strategic Initiatives 8.4.6. AlveoliX AG 8.4.6.1. Overview 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.6.3. Product Benchmarking 8.4.6.4. Strategic Initiatives 8.4.7. InSphero 8.4.7.1. Overview 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.7.3. Product Benchmarking 8.4.7.4. Strategic Initiatives 8.4.8. CN Bio Innovations Ltd 8.4.8.1. Overview 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.8.3. Product Benchmarking 8.4.8.4. Strategic Initiatives 8.4.9. ATTC Global 8.4.9.1. Overview 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.9.3. Product Benchmarking 8.4.9.4. Strategic Initiatives 8.4.10. TissUse GmbH 8.4.10.1. Overview 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit) 8.4.10.3. Product Benchmarking 8.4.10.4. Strategic Initiatives
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(バイオ薬物)の最新刊レポート
Grand View Research社の生物分野での最新刊レポート
本レポートと同じKEY WORD()の最新刊レポート
よくあるご質問Grand View Research社はどのような調査会社ですか?グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/12/20 10:28 158.95 円 165.20 円 201.28 円 |